A short news article about an early-stage clinical trial expansion testing higher doses of a candidate neurodegenerative drug, outlining safety and dosing goals and what readers can expect to learn.
Key Takeaways
- RTR 242 phase 1 enrollment increased from 76 to 108 participants for added dose cohorts
- Two higher-dose cohorts were added to identify tolerable dosing after no major safety signals
- Trial is conducted in healthy volunteers aged 18 to 65 in Australia